-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
2022 Hebei Two Sessions | Representative Tian Pengmei: Enhance Supporting Services to Further Boost the Pharmaceutical Industry
Category:
发布时间：2022-01-24
【概要描述】
“Over the past year, in pursuit of the goal of building a ‘modernized Hebei in six areas,’ our province has steadily accelerated its efforts to foster innovation-driven development and achieve leapfrog progress, with the pharmaceutical industry rapidly advancing to a leading position among China’s top-tier sectors,” said Tian Pengmei, a deputy to the Provincial People’s Congress, Assistant to the President and General Manager of the Strategic Development Center at Shijiazhuang Sihua Pharmaceutical Co., Ltd. She noted that favorable policies and a conducive business environment have further boosted the pharmaceutical sector, ushering in a golden period of growth for our province’s biopharmaceutical industry. She expressed hope that supporting services will be refined and strengthened as soon as possible to sustain and amplify this momentum.
“Over the past year, in pursuit of the goal of building a ‘modernized Hebei in six key areas,’ our province has steadily accelerated its efforts to foster innovation-driven development and achieve leapfrog progress, with the pharmaceutical industry rapidly advancing to a leading position among China’s top-tier sectors,” said Tian Pengmei, a deputy to the Provincial People’s Congress, Assistant to the President and General Manager of the Strategic Development Center at Shijiazhuang Sihua Pharmaceutical Co., Ltd. She noted that favorable policies and a conducive business environment have provided strong impetus for the pharmaceutical industry to redouble its efforts, ushering in a golden era of growth for our province’s biopharmaceutical sector. She expressed hope that supporting services will be further refined at an early date to continue driving the industry’s momentum.
Representative Tian Pengmei stated that sound policies are empowering the high-quality development of the pharmaceutical industry. Last year, the provincial, municipal, and district governments successively introduced a series of policies to support the development of the pharmaceutical sector and improve the business environment, providing financial assistance across the entire enterprise lifecycle—ranging from alleviating funding bottlenecks and fostering scientific research and innovation to offering talent incentives and subsidies. As a result, companies have accelerated the R&D and commercialization of new products: 32 new products were approved last year, four of which won bids in the national centralized drug procurement program, enabling rapid entry into the national market and generating more than RMB 800 million in additional sales within just six months.
As a representative from the grassroots level, Tian Pengmei has firsthand experience of the improvements in our province’s business environment. “The rapid development of enterprises is inseparable from the government’s targeted and precise services. Take Shijiazhuang as an example: the ‘Entrepreneurs–Mayor Symposium’ hosted by the municipal government, as well as the ‘Secretary’s Direct Line’ and ‘Secretary’s Breakfast Meetings’ launched by the High-tech Industrial Development Zone—these concrete initiatives to connect with and serve businesses are all squarely aimed at addressing specific problems, thereby smoothing communication channels with industrial development and helping enterprises resolve many of the difficulties and concerns they face in their survival and growth.” Representative Tian Pengmei stated that pragmatic and efficient government services enable enterprises to focus more on their products and markets, on innovation and R&D, and on high-quality development.
Speaking about advancing the sustainable innovation and high-quality development of our province’s pharmaceutical industry, Representative Tian Pengmei believes that addressing the shortcomings in service-sector support and making services more attentive and responsive is of great practical significance and far-reaching impact for enhancing our province’s capacity to attract, drive, and cluster industries. She proposes that, in light of the needs of industrial development, provincial-level branches of drug and medical-device inspection agencies could be established in key pharmaceutical-industry hubs such as Shijiazhuang High-tech Industrial Development Zone and Cangzhou Bohai New Area, thereby providing robust technical support for the development of our province’s biopharmaceutical sector and further improving the efficiency of industrial growth. At the same time, leveraging the government’s extensive network of connections with research institutes and other institutions, we should continuously deepen talent-service mechanisms, regularly assist enterprises in posting domestic and international talent-recruitment announcements and implementing the “listing-and-command” initiative, help firms overcome challenges related to talent shortages and critical research projects, and vigorously foster and strengthen leading enterprises and technology-driven champions in the industry, with the aim of driving high-quality development of the entire provincial pharmaceutical sector.
Representative Tian Pengmei stated that sound policies are empowering the high-quality development of the pharmaceutical industry. Last year, the provincial, municipal, and district governments successively introduced a series of policies to support the development of the pharmaceutical sector and improve the business environment, providing financial assistance across the entire enterprise lifecycle—ranging from alleviating funding bottlenecks and fostering scientific research and innovation to offering talent incentives and subsidies. As a result, companies have accelerated the R&D and commercialization of new products: 32 new products were approved last year, four of which won bids in the national centralized drug procurement program, enabling rapid entry into the national market and generating more than RMB 800 million in additional sales within just six months.
As a representative from the grassroots level, Tian Pengmei has firsthand experience of the improvements in our province’s business environment. “The rapid development of enterprises is inseparable from the government’s targeted and precise services. Take Shijiazhuang as an example: the ‘Entrepreneurs–Mayor Symposium’ hosted by the municipal government, as well as the ‘Secretary’s Direct Line’ and ‘Secretary’s Breakfast Meetings’ launched by the High-tech Industrial Development Zone—these concrete initiatives to connect with and serve businesses are all squarely aimed at addressing specific problems, thereby smoothing communication channels with industrial development and helping enterprises resolve many of the difficulties and concerns they face in their survival and growth.” Representative Tian Pengmei stated that pragmatic and efficient government services enable enterprises to focus more on their products and markets, on innovation and R&D, and on high-quality development.
Speaking about advancing the sustainable innovation and high-quality development of our province’s pharmaceutical industry, Representative Tian Pengmei believes that addressing the shortcomings in service-sector support and making services more attentive and responsive is of great practical significance and far-reaching impact for enhancing our province’s capacity to attract, drive, and cluster industries. She proposes that, in light of the needs of industrial development, provincial-level branches of drug and medical-device inspection agencies could be established in key pharmaceutical-industry hubs such as Shijiazhuang High-tech Industrial Development Zone and Cangzhou Bohai New Area, thereby providing robust technical support for the development of our province’s biopharmaceutical sector and further improving the efficiency of industrial growth. At the same time, leveraging the government’s extensive network of connections with research institutes and other institutions, we should continuously deepen talent-service mechanisms, regularly assist enterprises in posting domestic and international talent-recruitment announcements and implementing the “listing-and-command” initiative, help firms overcome challenges related to talent shortages and critical research projects, and vigorously foster and strengthen leading enterprises and technology-driven champions in the industry, with the aim of driving high-quality development of the entire provincial pharmaceutical sector.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091